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In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival 
Study (EPHESUS), eplerenone reduced morbidity and mortality in patients who had an acute 
myocardial infarction (MI), complicated by systolic dysfunction, HF or diabetes mellitus(1). 
In a prespecified secondary analysis of EPHESUS, Iraqi et al. reported concomitant 
reductions in the serum concentrations of N-terminal propeptide of type-I (PINP) and type-III 
(PIIINP) collagen, which may reflect an anti-fibrotic effect of eplerenone (2); however, the 
carboxy-terminal propeptide of procollagen type I (PICP) was not analyzed in that report. 
Studies of endomyocardial biopsies suggest that serum PIIINP and PICP (but not PINP 
fragments), reflect myocardial fibrosis (3) Moreover, PICP originates directly from the 
synthesis of collagen type-I in a 1:1 ratio, directly reflecting collagen type-I synthesis. On the 
other hand, PIIINP originates from partially processed procollagen molecules on the surface 
of collagen type III fibers. Therefore, serum PIIINP may not accurately reflect ongoing 
collagen type-III synthesis. Furthermore, a net release from the heart into the circulation has 
only been reported for PICP (and not for PIIINP) (4). Notwithstanding, for no good reason, 
trials of MRAs have focused more on PIIINP than on PICP.  
The type of collagen as well as the amount may be an important determinant of its 
effects on myocardial function. Collagen type-I comprises highly cross-linked, large-diameter 
fibers that have a major impact on stiffness whereas collagen type-III comprises mainly non–
cross-linked, small-diameter, more pliable fibers(3). Whether eplerenone also reduces serum 
PICP has not been reported thus far.  
We investigated the effect of eplerenone on serum concentrations of PICP in a 
substudy of EPHESUS(1). In EPHESUS, 6632 patients were randomized to either eplerenone 
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(up to 50 mg daily) or placebo, in addition to standard care. Compared to placebo, eplerenone 
reduced the occurrence of all-cause death and the combined endpoint of CV mortality and CV 
hospitalizations (for all-cause death: 14.4 vs 16.7% (RR 0.85; p=0.008; for CV mortality and 
CV hospitalizations: 26.7 vs. 30.0% (RR 0.87; p=0.002). 
In this biomarker substudy of EPHESUS, PICP was analyzed using an ELISA assay 
(Quidel, San Diego, CA, USA) at baseline (3-14 days after MI diagnosis) and at 9 months in 
peripheral blood samples of 227 patients (27% women, 48% randomized to eplerenone). 
These patients had similar baseline characteristics to those of the full cohort (data not shown). 
A detailed account of the methods of this biomarker substudy has been previously published 
(2). The number of patients included in this specific substudy was lower than the original 
biomarker substudy since not all patients had enough sample volume left for the measurement 
of PICP.  
Serum PICP at baseline was 99 ng/mL (IQR 77-129) and 97 ng/mL (IQR 77-120) in 
patients assigned to placebo and eplerenone, respectively; and at nine months 124 ng/mL 
(IQR 93-152) and 105 ng/mL (IQR 84-134) for placebo and eplerenone, respectively. The 
between group difference for the change in PICP was -16 ng/mL (95% CI -30 to -3) in favor 
of eplerenone using an analysis of covariance (ANCOVA) with the treatment and baseline 
PICP as covariates (Figure). Baseline levels of PICP were only modestly correlated with 
PIIINP and PINP (Spearman Rho of 0.29 and 0.34, respectively). Change in PICP from 
baseline to nine months was also only modestly correlated with change in PIIINP and PINP 
(Spearman Rho of 0.36 and 0.44, respectively).  
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After adjustment for eplerenone treatment and baseline PICP levels, a PICP decrease 
from baseline to month 9 was not significantly associated with all-cause mortality (adj. 1.24, 
95% CI 0.11-13.69, p=0.86) nor with the composite endpoint of cardiovascular death and 
cardiovascular mortality (adj HR 1.18, 95% CI 0.49-2.83, p=0.71). However, event rates in 
this substudy were very low (5 (2%) and 31 (14%) patients experienced all-cause mortality 
and CV death/CV hospitalization respectively), precluding any definitive conclusions 
regarding PICP changes and outcome associations. Larger studies need to further assess the 
prognostic value of changes in PICP and outcome in MI patients. 
 Persistent pro-fibrotic activity after an MI may contribute to a decline in cardiac 
function and the occurrence of arrythmias. Limiting excessive fibrosis may be a key 
mechanism by which eplerenone improved outcomes in the EPHESUS trial. These data 
suggest that eplerenone might limit the synthesis of collagen type-1 and retard or prevent 
excessive and potentially deleterious myocardial fibrosis. These beneficial effects may not be 
limited to patients with MI and/or HF since spironolactone (another MRA) also reduced PICP 
levels in patients at risk of developing HF in the HOMAGE trial (NCT02556450, results 
published at the HFSA meeting September 2019), suggesting that MRAs might be useful for 
HF prevention. In HOMAGE over 70% of the patients had a history of CAD, supporting the 
role of MRAs in limiting excessive fibrosis in the context of ischemia. 
It must be noted that for this substudy, PICP measurements were performed in 
samples that were stored for more than 15 years. Although PINP was stable over a duration of 
12 months at -80 degrees Celsius(5), data on long-term storage and stability of PICP is 
lacking. The possibility of degradation of PICP in time and/or skewness of the results can 
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therefore not be excluded. Moreover, a detailed cardiac function characterization (e.g. 
chamber volumes, diastolic function parameters) was not available; in consequence we cannot 
ascertain whether the change in PICP levels correlates (or not) with changes in cardiac 
structure and function. 
In conclusion, this is the first analysis to suggest a favorable effect of eplerenone on 
collagen type-1 synthesis which might contribute to its beneficial effects observed in patients 
after an MI, complicated with systolic dysfunction, HF or diabetes mellitus.  
 
Figure. PICP change from baseline to month 9. There was a significant between-group difference 
for the change in PICP from baseline to month 9 where PICP increased in the placebo group compared to no 
change in PICP in patients treated with eplerenone. In addition to between-group differences, a significant 
interaction between study treatment and within-subject PICP change was also observed (F (1,225) = 4.173, 
p=0.042, using mixed ANOVA). 
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